Results 171 to 180 of about 8,788 (204)
Some of the next articles are maybe not open access.
Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
New England Journal of Medicine, 2022Kalpana Gupta
exaly
Nirmatrelvir-Ritonavir (Paxlovid)
Canadian Journal of Health TechnologiesCADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire +1 more source
Paxlovid (nirmatrelvir/ritonavir).
WMJ : official publication of the State Medical Society of Wisconsin, 2022Kristin, Busse, Abir T, El-Alfy
openaire +1 more source
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Biomedicine and Pharmacotherapy, 2023AMIRHOSSEIN SHEIDA +2 more
exaly